公司资料
Merck 股价、新闻与催化剂
- 股票代码:
- MRK
- 交易所:
- NYSE
- 行业:
- Oncology, Immunotherapy, Vaccines
- 所在地:
- United States
股票表现
143.81 USD (-1.03%)
收盘价
最后更新: 2026年10月1日
286B USD
市值
股价为何变动
截至 2026年10月1日，MRK 下跌 1.03%，收于 $143.81。当前新闻监测窗口内未发现新的同公司新闻。
公司概览
Diversified Human and Animal Health Company
Merck, known as MSD outside the United States and Canada, is a global biopharmaceutical company with businesses in prescription medicines, vaccines, and animal health. Its human-health research spans oncology, infectious disease, vaccines, cardiometabolic and respiratory disease, immunology, neuroscience, and ophthalmology.
Oncology and the KEYTRUDA Franchise
Oncology is anchored by KEYTRUDA and subcutaneous KEYTRUDA QLEX, which are used across a broad range of solid tumors and hematologic malignancies. Merck is extending the franchise through earlier-stage treatment, perioperative regimens, and combinations with antibody-drug conjugates and targeted therapies. Its broader oncology pipeline includes sacituzumab tirumotecan, the personalized cancer vaccine intismeran autogene, KRAS inhibitor calderasib, and BCR::ABL1 inhibitor MK-4208.
Vaccines and Infectious Diseases
Merck has a large vaccine franchise spanning human papillomavirus, pneumococcal disease, respiratory syncytial virus, and other infectious diseases. The HIV portfolio combines approved daily treatment with investigational weekly and monthly approaches, including once-weekly islatravir and lenacapavir and once-monthly oral PrEP candidate alimatravir.
Cardiometabolic and Respiratory Medicines
The cardiometabolic portfolio includes WINREVAIR for pulmonary arterial hypertension and LIPFENDRA, an oral PCSK9 inhibitor for hypercholesterolemia. The acquisition of Verona Pharma added OHTUVAYRE for chronic obstructive pulmonary disease, expanding Merck's presence in respiratory medicine alongside a pipeline of cardiovascular and metabolic programs.
Immunology Pipeline
Merck is developing tulisokibart, an anti-TL1A antibody, across ulcerative colitis and other immune-mediated diseases. The program is part of a broader effort to build an immunology franchise through internally developed biologics and externally sourced assets that target inflammatory pathways with potential applications across gastrointestinal, dermatologic, and systemic autoimmune disorders.
Animal Health Business
Merck Animal Health markets medicines, vaccines, identification technologies, and health-management products for livestock and companion animals. The business provides an additional source of diversification and has expanded through acquisitions such as TARGAN, which added automated poultry vaccination and biodevice capabilities.
未来催化剂
- Planned global regulatory submissions for the once-weekly oral islatravir/lenacapavir HIV treatment regimen following positive Phase 3 ISLEND-1 and ISLEND-2 results.
- Presentation of full Phase 2 results for tulisokibart in hidradenitis suppurativa at an upcoming medical meeting.
近期新闻
新闻标题由机器翻译，详情为英文原文。
相似股票
商业成熟度、治疗领域或催化剂模式相近的同行公司。